Raydiant Oximetry
Clinical-stage maternal-fetal monitoring company building noninvasive fetal pulse oximetry and postpartum hemorrhage devices for labor and delivery settings.
What They Do
Raydiant Oximetry is developing Lumerah, a transabdominal fetal pulse oximetry system intended to measure fetal oxygen saturation directly during labor rather than relying only on fetal heart-rate tracing as a proxy for distress. The company also has a second device, Daisy, aimed at quantifying blood loss and improving uterine drainage after C-sections and other OB-GYN procedures. Public materials point to a classic hospital medtech model selling into labor-and-delivery units, health systems, and strategic platform partners rather than a reimbursed digital-health service. Its pitch is that better oxygenation data could reduce unnecessary emergency C-sections, improve detection of true fetal compromise, and lower downstream maternal-neonatal complication costs.
Competitive Position
Raydiant competes against incumbent fetal-monitoring stacks from GE HealthCare, Philips, and Monica/Novii-style systems that mainly rely on fetal heart-rate and contraction data rather than direct oxygenation measurement. It also competes with invasive adjuncts such as fetal scalp sampling when clinicians need better specificity during difficult labors. Raydiant's differentiation is that it is trying to create a noninvasive fetal oxygen-saturation layer that plugs into standard labor-and-delivery workflow while expanding into adjacent maternal devices like Daisy.
Funding Rounds
No funding rounds on record for this company.